Compare SYM & SRRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SYM | SRRK |
|---|---|---|
| Founded | 2005 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.5B | 6.8B |
| IPO Year | 2021 | 2018 |
| Metric | SYM | SRRK |
|---|---|---|
| Price | $40.57 | $54.15 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 13 |
| Target Price | ★ $62.50 | $56.17 |
| AVG Volume (30 Days) | ★ 1.6M | 979.3K |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.12 | N/A |
| Revenue | ★ $2,246,922,000.00 | N/A |
| Revenue This Year | $24.75 | N/A |
| Revenue Next Year | $27.90 | $534.24 |
| P/E Ratio | $352.92 | ★ N/A |
| Revenue Growth | ★ 25.65 | N/A |
| 52 Week Low | $38.19 | $27.07 |
| 52 Week High | $87.88 | $58.49 |
| Indicator | SYM | SRRK |
|---|---|---|
| Relative Strength Index (RSI) | 44.04 | 58.79 |
| Support Level | $39.09 | $44.26 |
| Resistance Level | $46.80 | $58.49 |
| Average True Range (ATR) | 2.04 | 2.30 |
| MACD | -0.09 | 0.45 |
| Stochastic Oscillator | 12.94 | 89.54 |
Symbotic Inc. is an automation technology company that develops solutions to improve operating efficiencies in modern warehouses. The group designs, commercializes, and deploys end-to-end technology systems that significantly enhance supply chain operations. The company automates the processing of pallets, cases, and individual items within warehouse environments. Its systems strengthen operations at the front end of the supply chain and provide benefits to all supply partners downstream. The company operates in two geographical regions: the United States and international markets, with the majority of its revenue generated in the United States.
Scholar Rock Holding Corp is a biopharmaceutical company focused on improving the lives of children and adults with Spinal Muscular Atrophy and other rare, severe, and debilitating neuromuscular diseases. Its pipeline candidates include apitegromab and a subcutaneous formulation of apitegromab. The clinical-stage pipeline also includes SRK-439, an investigational subcutaneously administered fully human anti-pro/latent myostatin antibody with high inhibitory potency and selectivity toward myostatin, being developed for the treatment of rare neuromuscular diseases. The company also maintains early-stage programs focused on therapies for rare, severe, and debilitating neuromuscular diseases.